2024
Impact and cost-effectiveness of the 6-month BPaLM regimen for rifampicin-resistant tuberculosis in Moldova: A mathematical modeling analysis.
James L, Klaassen F, Sweeney S, Furin J, Franke M, Yaesoubi R, Chesov D, Ciobanu N, Codreanu A, Crudu V, Cohen T, Menzies N. Impact and cost-effectiveness of the 6-month BPaLM regimen for rifampicin-resistant tuberculosis in Moldova: A mathematical modeling analysis. PLOS Medicine 2024, 21: e1004401. PMID: 38701084, PMCID: PMC11101189, DOI: 10.1371/journal.pmed.1004401.Peer-Reviewed Original ResearchQuality-adjusted life yearsStandard of careDrug susceptibility testingRifampicin-resistant tuberculosisRR-TBEnd-of-treatmentLonger regimensTreatment strategiesTreatment outcomesBurden of drug-resistant TBCost-effective treatment strategyResistance to amikacinDrug-resistant TBSevere adverse eventsHistory of TBResistance to delamanidTB drug resistanceAnti-TB drugsLifetime costsAssociated treatment outcomesFQ-R.Average timeNatural history of TBFluoroquinolone resistanceFQ-R
2023
Global burden of disease due to rifampicin-resistant tuberculosis: a mathematical modeling analysis
Menzies N, Allwood B, Dean A, Dodd P, Houben R, James L, Knight G, Meghji J, Nguyen L, Rachow A, Schumacher S, Mirzayev F, Cohen T. Global burden of disease due to rifampicin-resistant tuberculosis: a mathematical modeling analysis. Nature Communications 2023, 14: 6182. PMID: 37794037, PMCID: PMC10550952, DOI: 10.1038/s41467-023-41937-9.Peer-Reviewed Original ResearchConceptsDisability-adjusted life yearsRifampicin-resistant tuberculosisRR-TBGlobal burdenSubstantial short-term morbidityRifampicin-susceptible tuberculosisShort-term morbidityOverall disease burdenLong-term health impactsPost-treatment careTB survivorsDisease burdenTreatment outcomesTuberculosis survivorsCase detectionLife yearsRifampicin resistanceTuberculosisHealth impactsBurdenHealth expenditureDiseaseSurvivorsMathematical modeling analysisFormer Soviet Union countries
2020
Ongoing challenges to understanding multidrug- and rifampicin-resistant tuberculosis in children versus adults
McQuaid CF, Cohen T, Dean AS, Houben RMGJ, Knight GM, Zignol M, White RG. Ongoing challenges to understanding multidrug- and rifampicin-resistant tuberculosis in children versus adults. European Respiratory Journal 2020, 57: 2002504. PMID: 32855219, DOI: 10.1183/13993003.02504-2020.Peer-Reviewed Original ResearchConceptsMDR/RR-TBRR-TBOdds ratioPediatric TB casesGlobal TB epidemicRifampicin-resistant tuberculosisPopulation-representative surveyTB casesBurden countriesTB epidemicMost settingsTuberculosisDrug resistanceTransmission riskCountry-specific estimatesAdultsChildrenAgeFurther investigationMultidrugOddsFormer Soviet Union countriesSufficient dataSettingSoviet Union countries
2017
Priority-Setting for Novel Drug Regimens to Treat Tuberculosis: An Epidemiologic Model
Kendall EA, Shrestha S, Cohen T, Nuermberger E, Dooley KE, Gonzalez-Angulo L, Churchyard GJ, Nahid P, Rich ML, Bansbach C, Forissier T, Lienhardt C, Dowdy DW. Priority-Setting for Novel Drug Regimens to Treat Tuberculosis: An Epidemiologic Model. PLOS Medicine 2017, 14: e1002202. PMID: 28045934, PMCID: PMC5207633, DOI: 10.1371/journal.pmed.1002202.Peer-Reviewed Original ResearchConceptsEase of adherenceTB mortalityTB incidenceNovel drug regimensTB regimenNovel regimenDrug regimensRegimen characteristicsTreatment durationTreatment efficacyRR-TB treatmentTB treatment efficacyRifampicin-resistant TBTB treatment durationDynamic transmission modelTB regimensNew regimensRR-TBTB treatmentMedical contraindicationsPatients' qualitySafety profileBaseline prevalenceTB epidemicTuberculosis treatment